Physician profile
Robert Wiencek
NPI 1609902279
$2,184.98
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,276 · 2020: $404 · 2021: $470 · 2022: $35.29.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $619.09 | 2019-2020 | |
| Medtronic Vascular, INC. | $528.28 | 2019-2020 | |
| Abiomed | $273.53 | 2019-2022 | |
| Getinge USA Sales, LLC | $216.07 | 2019-2021 | |
| Baxter Healthcare | $155.06 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $124.31 | 2020-2021 | |
| Medtronic, INC. | $90.33 | 2021 | |
| Bard Peripheral Vascular, INC. | $64.84 | 2019 | |
| Inari Medical, INC. | $47.64 | 2021 | |
| Davol INC. | $23.57 | 2020 | |
| Kls-Martin L.P. | $21.48 | 2021 | |
| Viiv Healthcare Company | $20.78 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wiencek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.